FDA Clears Quidel's Solana MDx Platform, Group A Strep Assay

Jun 23, 2015

|

NEW YORK (GenomeWeb) – Quidel said today that the US Food and Drug Administration cleared the firm's Solana molecular platform and associated Group A Streptococcus assay.

Solana leverages the helicase-dependent amplification technology that also underpins Quidel's AmpliVue molecular technology. Solana can process up to 12 patient samples in a 30-minute run, saving time for healthcare professionals in moderately complex settings, Quidel said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Commission's First Meeting

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

More Scrutiny

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Web of Neutrophil DNA

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

Science Explores Method to Infer Genotype-by-Environment Interactions

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.

Featured White Papers

BlueBee Data Security & Compliance

Menu